Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study.

David Nanchen David Carballo Stefan Bilz Hans RickliKonstantinos C KoskinasFrançois Mach Christian E Mueller Carmela Crljenica Mariagrazia Rossi Nina Reichert Isabella Sudano

Published in: Advances in therapy (2021)

In real-world clinical practice, evolocumab was mainly used in patients with statin intolerance and pre-existing CVD. In this population, adherence to evolocumab and low LDL-C levels were maintained over 1 year, with better LDL-C goal achievement in patients using evolocumab in combination with other lipid-lowering drugs. Safety of evolocumab was similar to that documented in randomized controlled trials.

Keyphrases

low density lipoprotein
randomized controlled trial
end stage renal disease
clinical practice
chronic kidney disease
newly diagnosed
ejection fraction
systematic review
prognostic factors
type diabetes
cross sectional
fatty acid
patient reported outcomes
glycemic control
weight loss